Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:NVLN

Novelion Therapeutics (NVLN) Stock Price, News & Analysis

Novelion Therapeutics logo

About Novelion Therapeutics Stock (NASDAQ:NVLN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.68
$0.70
52-Week Range
N/A
Volume
26,947 shs
Average Volume
190,529 shs
Market Capitalization
$13.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NVLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novelion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NVLN Stock News Headlines

CYTO - Altamira Therapeutics Ltd.
See More Headlines

NVLN Stock Analysis - Frequently Asked Questions

Novelion Therapeutics Inc. (NASDAQ:NVLN) released its quarterly earnings results on Thursday, March, 14th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by $0.13. The biotechnology company had revenue of $40.71 million for the quarter, compared to the consensus estimate of $40.90 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Novelion Therapeutics investors own include Aralez Pharmaceuticals (ARLZ), Applied Genetic Technologies (AGTC), Biocept (BIOC), Bristol Myers Squibb (BMY), Karyopharm Therapeutics (KPTI), Actinium Pharmaceuticals (ATNM) and Amicus Therapeutics (FOLD).

Company Calendar

Last Earnings
3/14/2019
Today
7/10/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NVLN
CIK
827809
Fax
N/A
Employees
109
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$108.33 million
Net Margins
-79.43%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-26.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.24
Quick Ratio
0.21

Sales & Book Value

Annual Sales
$130.43 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.69) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
19,619,000
Free Float
N/A
Market Cap
$13.77 million
Optionable
Optionable
Beta
2.12
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:NVLN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners